Efficacy and safety of using colistin in neonates

The rate of health care-associated infections (HCAI) leading to mortality and morbidity in neonatal intensive care units (NICU) was estimated as 7 –24%.1 Increasing reports of HCAI being caused by multidrug-resistant Gram-negative bacilli (MDR-GNB), such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, is worrisome.2–4 Using effective drugs on time correlated with less mortality due to bacteremia; therefore,2, 3 it is important to initiate an effective and safe regimen for treating MDR-GNB infections in neonatal patients.
Source: Pediatrics and Neonatology - Category: Perinatology & Neonatology Authors: Tags: Editorial Source Type: research